Skip to main content
. 2022 Oct 12;25(1):4–25. doi: 10.1093/neuonc/noac207

Figure 7.

Figure 7.

Targeted therapies for IDH-mutant gliomas. Oncogenic mechanisms and metabolic reprogramming caused by mutant IDH and excess D-2-hydroxyglutarate (D-2-HG). Targeting strategies under investigation are noted at relevant points.